Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Incyte's Povorcitinib?
Povorcitinib is a small molecule commercialized by Incyte, with a leading Phase III program in Hidradenitis Suppurativa. According to Globaldata,...
Data Insights
Risk adjusted net present value: What is the current valuation of Incyte's Povorcitinib?
Povorcitinib is a small molecule commercialized by Incyte, with a leading Phase III program in Hidradenitis Suppurativa. According to Globaldata,...